Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific targets on cancer cells, triggering their destruction directly or flagging them for elimination by your immune system. Drugs such as rituximab (lymphoma, CLL), trastuzumab (HER2+ breast cancer), bevacizumab and many others are now part of standard-of-care regimens for a wide range of cancers. At Dr. Joshi's Cancer Centre, these agents are administered under direct medical supervision with careful pre-medication and infusion monitoring. We ensure every patient receiving monoclonal antibody therapy is fully informed about the mechanism, expected benefits, potential infusion reactions and long-term considerations.
